Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering

Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication demonstrates stable, cell-specific transgene expression through in vivo site-specific integration of large DNA payloadsFindings show integration of a promoterless CAR at the TRAC locus enables physiologic CAR expression and durable anti-tumor activity in preclinical models BERKELEY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today highlighted the publication of foundational research in Nature describing in vivo site-specific genomic integration to reprogram T cells. The research originated as an academic collaboration between the Eyquem laboratory at the University of California, San Francisco and the Doudna laboratory at the University of California, Berkeley. Three of the study's authors - Justin Eyquem, Ph.D., Jenny Hamilton, Ph.D. and Jennifer Doudna, Ph.D. - subsequently co-founded Azalea Therapeutics to advance precise, programmable in vivo cell engineering toward the development of next-generation in vivo CAR T and other cell-based therapies.

Read Full Article →